Thank you, Mr. Member.
Let me try to address the isotopes in Canada, which is your concern, and then we can talk about your request for tabling, if you wish.
First of all, it should be recognized that, as I laid out in my production chain, the isotopes that are produced in a reactor do not go directly to patients; they have to go to a radiopharmaceutical manufacturer and then to the patients. Whether that comes from the NRU reactor in Canada, the BR2 reactor in Belgium, the Osiris reactor in France, or the Petten reactor in the Netherlands, it is all the same.
I would like to inform you that we were in constant contact with IRE in Belgium, the operators of the Mol facility at BR2. In fact, we wrote them a letter from our president on November 30 imploring them to provide product to Canada. As I mentioned in my testimony, in spite of our constant discussions with them, in spite of imploring them vigorously, we did not receive anything until December 14, two days after the legislation was passed.
I would also like to address the point you made about the restart of the NRU reactor. The NRU reactor was in a scheduled maintenance shutdown when we were informed about this on November 21. It was at about that time, in fact, that the NRU reactor was to restart after its routine maintenance shutdown. So we were in a supply shortage, which started on about November 21, until Parliament acted to restart the reactor, a period of some three weeks.
I'm not sure what Mr. Ponsard might have told you, what Mr. Ponsard was implying, but in fact Mr. Ponsard was one of the people we conferred with to obtain isotope from Belgium.